Clinical Trials Logo

Clinical Trial Summary

This trial is a multi-center, open, single-arm, superior phase II clinical study.


Clinical Trial Description

The study included 40 patients with gastric cancer or gastroesophageal junction adenocarcinoma with clinical stage T3-4aN+M0; and confirmed after HER2 IHC results Patients with medium and high expression of HER2 (defined as: IHC 2+ 3+); the neoadjuvant treatment plan is: disitamab vedotin + PD-1 + capecitabine; the main goal of the study is to explore The effectiveness of disitamab vedotin combined with PD-1 monoclonal antibody and capecitabine in the neoadjuvant treatment of locally advanced gastric or gastroesophageal junction adenocarcinoma, and ultimately provide a basis for the update of treatment decisions for locally advanced gastric or gastroesophageal junction adenocarcinoma Proof of medical evidence. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05113459
Study type Interventional
Source Nanfang Hospital of Southern Medical University
Contact liying zhao, PhD
Phone 13430396746
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date December 18, 2021
Completion date June 18, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03746704 - Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Participants With Advanced PD-L1 Positive Malignancies Phase 1
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT05052931 - Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer Phase 2
Recruiting NCT04082364 - Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Active, not recruiting NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04062656 - Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG Phase 2
Recruiting NCT04354662 - Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer Phase 2
Recruiting NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Not yet recruiting NCT03273920 - Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT04553692 - Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and/or Refractory Solid Cancers Phase 1
Active, not recruiting NCT04842916 - InteGRAtive Analysis of tuMor, Microenvironment, immunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer